Amgen beat Q1 estimates with strong margins driven by Blincyto, Prolia, and standout Imdelltra growth, plus strength in ...

The exercise prescriptions also prevented other new cancers, like breast and prostate cancer. Many included just three to ...

BERWYN, PA — Panavance Therapeutics Inc. has shared promising interim findings from its ongoing Phase 1 clinical trial ...

Cemiplimab improved disease-free survival in patients with high-risk cutaneous squamous cell carcinoma (CSCC) and performed ...

Treating patients with lung cancer always calls for a focus on informed and shared decision-making, according to expert ...

Late-stage pipeline products can generate demand in the MG market and with diagnosed prevalent cases, will drive growth in ...

Dr. Joshua K. Sabari and Dr. Prantesh Jain delve into key lung cancer outcomes from the 2025 ASCO Meeting that patients should be aware of.

A retrospective study presented at the recent American Society of Clinical Oncology (ASCO) meeting suggested that patients ...

Interim analysis shows misetionamide is very well tolerated in combination with gemcitabine; rates of confirmed response, stable disease, and progression-free survival compare favorably with ...

Big news! ASCO lands a major nine-figure contract with a North Sea operator. This game-changer highlights our 60 years of ...

Compared with chemotherapy alone, neoadjuvant nivolumab plus chemotherapy extends overall survival in patients with resectable non-small cell lung cancer.

Artificial intelligence (AI)-assisted training improves pathologist accuracy in human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) scoring in patients with breast cancer.